Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

$RPRX at just $35M mkt cap today but recent Approval is very positive for shares.

|Includes: Repros Therapeutics Inc. (RPRX)
Approval to Commence Phase IIb Study of Androxal® in the Treatment of Secondary Hypogonadism 
Remember in 2008 market players thought RPRX was cheap @ $121.4M mkt cap because of its $3.5B rev. potential from its pipeline.